Efficacy of mesenchymal stem cell therapy on glucose levels in type 2 diabetes mellitus: A systematic review and meta‐analysis

Abstract

Aims/Introduction: In recent years, mesenchymal cellular therapies have received much attention in the treatment of diabetes. In this meta-analysis, we aimed to evaluate the efficacy of mesenchymal stem cell therapy in type 2 diabetes mellitus patients. Materials and Methods: A comprehensive literature search was carried out using PubMed, Scopus, Web of Science and Central databases. A total of 1,721 articles were identified, from which nine full-text clinical trials were qualified to enter the current metaanalysis. The assessment groups included patients with type 2 diabetes, and levels of Cpeptide, glycosylated hemoglobin and insulin dose were analyzed before and after mesenchymal stem cell infusion. Data analysis was carried out in Stata version 11, and the Jadad Score Scale was applied for quality assessment. Results: Changes in levels of C-peptide after mesenchymal stem cell therapy were: standardized mean difference 0.20, 95% confidence interval -0.61 to 1.00, glycosylated hemoglobin levels were: standardized mean difference -1.45, 95% confidence interval -2.10 to -0.79 and insulin dose were: standardized mean difference -1.40, 95% confidence interval -2.88 to 0.09. Conclusions: This meta-analysis of prospective studies showed associations between mesenchymal stem cell therapy and control of glucose level in patients with type 2 diabetes.

RETRACTED ARTICLE: Mesenchymal stem cell-derived exosomal miR-146a reverses diabetic β-cell dedifferentiation

“…Recently, mesenchymal stem cell (MSC)-based therapy has offered a promising strategy for treating diabetes. Some clinical studies have found that MSCs and their derivatives can significantly improve fasting blood glucose, C-peptide levels, HbA1c levels, and insulin secretion [8][9][10], with no significant side effects having yet been observed. Among MSCs, bone marrow MSCs (bmMSCs) have shown significant effects in regulating β-cell mass and in ameliorating chronic high-glucoseinduced β-cell injury [11,12].…”

Reconstitution and post-thaw storage of cryopreserved human mesenchymal stromal cells: Pitfalls and optimizations for clinically compatible formulants

“…In 2022, more than 1000 clinical trials applying MSCs were registered at clinicaltrials.gov . The spectrum of conditions targeted by MSC-based therapies is broad, ranging from systemic MSC treatments in type 2 diabetes, solid organ transplantation, and graft versus host disease to localized MSC therapies in osteoarthritis, inflammatory bowel disease, soft tissue regeneration, and degenerative disc disease [ [3] , [4] , [5] , [6] , [7] , [8] , [9] ]. Both autologous and allogenic MSCs are investigated as a therapeutic entity.…”

Transient coating of intestine in type 2 diabetic patients: Pilot trial outcome of Glucolate

“…According to a cross-sectional analysis of data from the National Health and Nutrition Examination Survey [7], only 50% of US adults with T2D achieve optimal glycemic control. Although stem cell implantation has also shown some potential in diabetic control, it is not yet widely used as a standard approach [8]. For patients with refractory T2D and a body mass index (BMI) of 30 kg/cm 2 (27.5 in Asian populations) or greater, bariatric surgery such as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) has been considered the most effective therapeutic option and has been included in diabetic management recommendations and guidelines [9][10][11].…”